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N-Myc Downstream-Regulated 
Gene 2 (NDRG2) as a Novel 
Tumor Suppressor in Multiple 
Human Cancers
Jian Zhang, Xia Li, Liangliang Shen, Yan Li and Libo Yao
Abstract
N-myc downstream-regulated gene 2 (NDRG2) was identified as a novel tumor sup-
pressor gene in regulating the proliferation, differentiation, apoptosis and metastasis of 
multiple cancer types. Consistent with this finding, we and other groups observed the 
decreased NDRG2 expression in multiple human cancer cell lines and tumors, including 
breast cancer, colorectal cancer, and cervical cancer. We identified NDRG2 as a stress 
sensor for hypoxia, DNA damage stimuli and endoplasmic reticulum stress (ERS). Our 
recent data showed that NDRG2 could promote the differentiation of colorectal cancer 
cells. Interestingly, we found that reduced NDRG2 expression was a powerful and 
independent predictor of poor prognosis of colorectal cancer patients. Furthermore, 
NDRG2 can inhibit epithelial-mesenchymal transition (EMT) by positively regulating 
E-cadherin expression. Moreover, NDRG2-deficient mice show spontaneous develop-
ment of various tumor types, including T-cell lymphomas, providing in vivo evidence 
that NDRG2 functions as a tumor suppressor gene. We believe that NDRG2 is a novel 
tumor suppressor and might be a therapeutic target for cancer treatment.
Keywords: NDRG2, tumor suppressor, stress sensor, p53, differentiation, EMT, 
metastasis, cancer metabolism
1.  The finding of NDRG2
The human NDRG2 sequence was first described by Deng et al. as a protein contain-
ing an acyl-carrier protein (ACP)-like domain [1, 2]. The gene was cloned from differen-
tially expressed genes between glioblastoma and normal brain tissues using PCR-based 
subtractive hybridization in 2003 [2]. NDRG2, NDRG1, NDRG3, and NDRG4 comprise 
the NDRG gene family and share approximately 59–68% homology. Additionally, 
NDRG family members display over 92% homology between humans and mice [1].
We identified NDRG2 as a novel tumor suppressor gene that plays a role in regu-
lating the proliferation, differentiation, apoptosis and metastasis of multiple types of 
malignant tumors [1, 2]. Consistent with this finding, NDRG2 downregulation has 
been observed in multiple human cancer cell lines and tumors [3–5]. Additionally, 
other groups later confirmed our finding [6, 7]. NDRG2 was identified as a stress 
sensor for hypoxia, DNA damage stimuli and endoplasmic reticulum stress (ERS), 
and could inhibit the proliferation and promote the differentiation of colorectal 
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carcinoma cells [8]. Moreover, NDRG2-deficient mice show spontaneous develop-
ment of various tumor types, providing in vivo evidence that NDRG2 functions as 
a tumor suppressor gene. In this chapter, we will introduce the recent findings of 
NDRG2 as tumor suppressor in vitro and in vivo, and also the detailed mechanism.
2. NDRG2 as a hypoxia and DNA damage responder
Our group firstly identified NDRG2 as a protein containing an acyl-carrier 
protein (ACP)-like domain. The gene was cloned from differentially expressed 
genes between glioblastoma and normal brain tissues using PCR-based subtractive 
hybridization in 2003. NDRG2, NDRG1, NDRG3, and NDRG4 comprise the NDRG 
gene family [1] and share approximately 59–68% homology. Additionally, NDRG 
family members display over 92% homology between humans and mice.
The expression and cellular localization of NDRG2 were altered following 
exposure to different stresses, supporting the role of NDRG2 as a cellular stress sen-
sor. Wang et al. found that NDRG2 expression was markedly upregulated in several 
cancer cell lines exposed to hypoxic conditions or similar stresses at both the mRNA 
and protein levels [9]. Hypoxia-inducible factor-1α (HIF-1α) can directly bind to 
hypoxia response elements (HREs) in the NDRG2 promoter, thus upregulating 
NDRG2 expression under hypoxia. Importantly, enforcing the expression of NDRG2 
can strongly increase the apoptosis of cancer cells. Alternatively, NDRG2 can translo-
cate from the cytoplasm to the nucleus under DNA damage stress. However, no 
explicit nuclear localization signal (NLS) sequence has been identified in the NDRG2 
protein. Although NLSs are the most common type of nuclear import elements, 
other mechanisms may also be involved in NDRG2 translocation. For example, Liu 
et al. and Cao et al. confirmed that NDRG2 was upregulated by p53 or adriamycin 
(ADR) treatment [10, 11]. Thus, NDRG2 can translocate into the nucleus and 
increase p53-dependent cell apoptosis through the DNA damage repair mechanism. 
Furthermore, we found that NDRG2 expression was decreased in ADR-resistant 
breast cancer cells. However, NDRG2 rescue could promote ADR sensitivity through 
inhibiting proliferation and promoting cellular damage responses and apoptosis 
in a p53-dependent manner. Interestingly, we found that NDRG2 upregulated Bad 
expression by increasing its half-life, which is associated with p53 expression in 
mitochondria. Thus, NDRG2 promoted the therapeutic sensitivity of breast cancer 
cells in a p53-dependent manner by preventing p53 from entering the nucleus to 
participate in DNA damage repair rather than by changing its expression [12].
We first found that NDRG2 is positively regulated by p53. The first intron of the 
NDRG2 gene contains a site that binds p53 directly and mediates wild-type (WT) 
p53-dependent transactivation [11]. In addition, NDRG2 enhances p53-mediated 
apoptosis, whereas overexpression of NDRG2 suppresses tumor cell growth inde-
pendently of p53 mutation. NDRG2 enhances p53-mediated apoptosis of hepatocar-
cinoma cells by downregulating ERCC6 (also named cockayne syndrome B—CSB) 
expression, which is critical for nucleotide excision repair capacity [10]. Thus, exci-
sion repair cross-complementing complementation group 6 (ERCC6) is an NDRG2-
inducible target gene that is involved in the p53-mediated apoptosis pathway.
3.  NDRG2 functions as a novel ER stress-responsive protein and 
unfolded protein response (UPR) modulator
The ER is an essential organelle involved in many cellular processes, including 
protein folding and maturation, lipid synthesis and calcium homeostasis. When 
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cells are challenged by different environmental or intracellular insults, such as 
energy or nutrient deficiency, hypoxia, or oxidative stresses, ER’s function is 
disrupted, causing accumulation of unfolded or misfolded proteins in the ER, a 
condition which is defined as ER stress [13, 14]. This triggers integrated signaling 
pathways to deal with the unfolded proteins, a phenomenon known as the UPR, 
which operates to restore ER homeostasis or, alternatively, lead to cell death under 
prolonged or severe ER stress [13, 14].
The UPR contains three branches initiated by three ER-resident transmembrane 
sensors: protein kinase RNA-like ER kinase (PERK), inositol-requiring enzyme 1α 
(IRE1α), and activating transcription factor 6 (ATF6) [15]. ER stress and the UPR 
are intensively involved in not only physiological conditions but also the pathogen-
esis of many diseases, including cancer [14, 16]. Accumulating implicates ER stress 
and the UPR in different aspects of tumorigenesis and tumor progression.
NDRG2 is a stress-responsive gene [1], and our laboratory recently reported 
that as such, NDRG2 is implicated in ER stress [17] in addition to the hypoxia 
and DNA damage response. Different ER stress inducers, including thapsigargin 
(Tg), tunicamycin (Tm) and dithiothreitol (DTT), can induce NDRG2 mRNA and 
protein expression in human hepatoma SK-Hep-1 and HepG2 cells. In NDRG2-
overexpressing hepatoma cell lines and Ndrg2 knockout (KO) mouse liver tissues, 
among the three UPR branches, NDRG2 interacts with PERK upon ER stress and 
facilitates PERK pathway activity, enhancing downstream ATF4 and CHOP activity. 
Thus, overexpression of NDRG2 promotes ERS-induced apoptosis, while silencing 
or knockdown of NDRG2 does the opposite, both in cell lines and in vivo. These 
data suggest that NDRG2 is a novel ER stress-responsive protein and an important 
component of the UPRosome, acting as a PERK cofactor to facilitate PERK branch 
signaling and thereby contributing to ER stress-induced apoptosis [17]. Therefore, 
apart from its already established role, NDRG2 could be considered a component 
of the UPRosome and a key player in cell fate decisions during ER stress. However, 
whether NDRG2 regulates PERK by affecting its dimer/oligomer status or its 
post-translational modification or by competing with other regulators for binding is 
worthy of further investigation.
4. NDRG2 as a novel prognostic biomarker in cancer
NDRG2 expression is mainly detected in the muscle, brain, heart, liver, colon 
[18]. Interestingly, NDRG2 expression is nearly undetectable in the thymus, the 
bone marrow, the testis, and peripheral blood leukocytes, suggesting an inverse 
correlation between the NDRG2 gene expression level and cell proliferation status 
[18–20]. We and other groups confirmed the pattern of decreased NDRG2 expres-
sion in tumors compared with normal tissues in cancers including glioma [2, 19, 21], 
colorectal cancer [8, 22, 23], breast cancer [3, 24], lung cancer [25], thyroid cancer 
[26, 27], myeloid leukemia [28, 29] oral squamous cell carcinoma (OSCC) and 
cervical cancer [5, 7]. Collectively findings from these studies indicate that NDRG2 
expression is decreased in most tumors. Moreover, NDRG2 expression was posi-
tively correlated with tumor differentiation but negatively correlated with lymph 
node metastasis and TNM stage (Figure 1).
We used a hospital-based study cohort of 226 colorectal cancer patients to 
analyze the correlation of NDRG2 mRNA levels with the tumor clinicopathologic 
features, disease-free survival, and overall survival of colorectal cancer patients. 
NDRG2 mRNA expression was significantly correlated with differentiation status, 
lymph node metastasis, and tumor-node-metastasis stage [23]. Patients with reduced 
NDRG2 mRNA levels had significantly worse progression-free survival (PFS) and 
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overall survival (OS) than patients with preserved expression of NDRG2 mRNA. We 
provided the first evidence that the NDRG2 mRNA level is a novel independent 
prognostic biomarker for both PFS and OS in colorectal cancer patients [23].
Another study analyzed NDRG2 expression in 127 bladder cancer patients and 
97 healthy controls. Similar to the findings in colorectal cancer, NDRG2 expression 
was significantly downregulated at both the mRNA and protein levels in the urine 
of patients with bladder cancer and was independently correlated with tumor grade 
and stage [30]. Thus, NDRG2 expression was decreased in patients with bladder can-
cer and might be a potential independent diagnostic biomarker for bladder cancer.
5. NDRG2 and differentiation
Differentiation deficiency is a key characteristic of cancer. Poorly differentiated 
cancers show high proliferation and metastasis capacities, which seriously impact 
patient survival and prognosis [31]. As a member of the human NDRG gene family, 
the involvement of NDRG2 in the regulation of cell differentiation has been fully 
addressed. Bioinformatics analysis of NDRG2 revealed several binding sequences 
for different transcription factors, which are mostly involved in growth regulation 
and early differentiation.
As a master switch for cell proliferation and differentiation, Myc performs its bio-
logical functions mainly through transcriptional regulation of its target genes, which 
are involved in cell interaction and communication with their external environment 
[32, 33]. We first provided the evidence that NDRG2 is transcriptionally repressed by 
Myc [34]. In addition, c-Myc overexpression dramatically reduced NDRG2 protein 
and mRNA levels. The core promoter region of NDRG2 is required for Myc-mediated 
repression of NDRG2 transcription, and the interaction of Myc with the core pro-
moter region was verified both in vitro and in vivo. A mechanistic study showed that 
Miz-1 is involved in Myc-mediated NDRG2 repression, and is possibly through the 
recruitment of other epigenetic factors, such as histone deacetylases, to the promoter.
Figure 1. 
The molecular working model of NDRG2. NDRG2 can be transcriptionally upregulated by p53 and  
KLF4, and repressed by Myc. NDRG2 inhibited cancer cells proliferation through blocking PI3K/Akt signaling, 
promoted colorectal cancer cells differentiation through decreasing SKP2 and increasing p21/p27 expression, 
inhibited EMT through Snail abrogation, and sensitized cancer cells to chemotherapy with DNA damage repair 
inhibition.
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In colorectal cancer, the vast majority of poorly differentiated cells contain con-
stitutive activation of WNT/β-catenin signal. WNT signaling-activating truncation 
mutations in adenomatous polyposis coli (APC) induce the nuclear translocation 
of β-catenin is induced, and consequently contributes to cell-fate determination 
via β-catenin/TCF complexes [35–38]. GSK-3β phosphorylates β-catenin at criti-
cal serine and threonine residues in its N terminus, which earmarks β-catenin for 
ubiquitination by the SCF complex and for subsequent degradation by the protea-
some pathway [39, 40]. GSK-3β inactivation by APC mutation or oncogenic PI3K/
AKT activation leads to the β-catenin/TCF complex formation, and further induced 
TCF target gene expressions, such as Myc, cyclin D1 [41, 42]. NDRG2 suppresses 
β-catenin nuclear translocation and decreases the occupancy of β-catenin/TCF 
complex on the promoter of E3 ligase Skp2, potentially through dephosphorylating 
AKT and GSK-3β. NDRG2-mediated suppression of Skp2 contributes to the induc-
tion and stabilization of p21 and p27, which are target proteins for Skp2-mediated 
degradation. Thus, NDRG2-meidated induction of cell differentiation is dependent 
on suppressing the activity of the Skp2 E3 ligase. In support of the biological 
significance of the reciprocal relationship between NDRG2 and Skp2, an NDRG2low/
Skp2high gene expression signature correlates with poor patient outcome and could 
be considered as a diagnostic marker for colorectal cancers.
Additionally, other groups have provided evidence of NDRG2 involvement 
of cell differentiation induced by different transcription factors, such as Wilms’ 
tumor gene 1 (WT1) protein, HIF-1α and glucocorticoids [33, 54, 55]. Through an 
oligonucleotide array approach, WT1 was found to indirectly or directly induce the 
expression of NDRG2 mRNA in CD34+ cells and in leukemic U937 cells through 
an [54]. Moreover, a novel start site for NDRG2 expression appeared to be used in 
WT1-transduced cells, suggesting that this promoter is utilized preferentially when 
high levels of WT1 are present [54].
6. NDRG2 inhibits EMT and cancer metastasis
Metastasis is a unique feature of tumor cells and an important factor affecting 
the survival and prognosis of cancer patients; it is also an important reason that sur-
gery cannot completely remove tumor lesions. EMT is an important process preced-
ing tumor metastasis [43, 44]. During EMT, tumor cells change from an epithelioid 
morphology to a mesenchymal cell morphology. The adhesion abilities between 
cells were decreased [45, 46]. Various signaling pathways were found involved in 
the regulation of EMT, such as, TGF-β pathway [47], Wnt/β-catenin pathway [48] 
and Notch pathway [49].
Data indicate that NDRG2 is negatively regulated by TGF-β during the progres-
sion of hepatocellular carcinomas [6]. This observation may be due to impairment 
in the TGF-β/Smad signaling pathway or the activation of non-Smad signaling 
cascades (PI3K/AKT, p38MAPK and so on) in these cell lines in response to TGF-β. 
Accordingly, related evidence has shown that the enhancement of GSK-3β activity 
by NDRG2 overexpression causes proteasomal degradation of the Snail transcrip-
tion factor and subsequent transcriptional regulation of EMT-related genes [50]. 
Thus, the tumor suppressor NDRG2 could inhibit TGF-β-induced EMT as well as 
cell invasion and migration in various cancers. Similarly, a study showed the inhibi-
tory effect of NDRG2 on TGF-β-induced tumor metastasis via the attenuation of 
active autocrine TGF-β production [51].
In breast cancer, NDRG2 downregulated the expression of Snail, as well as the 
phosphorylation of signal transducer and activator of transcription 3 (STAT3), an 
oncogenic transcription factor activated in many human malignancies, including 
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breast cancer [24]. Further, NDRG2 overexpressing breast cancer cells showed 
markedly decreased Snail expression after treatment with STAT3 inhibitors. Thus, 
the inhibition of STAT3 signaling by NDRG2 suppresses EMT progression via the 
down-regulation of Snail expression. Moreover, high NDRG2 expression induced 
inactivation of NF-κB and PI3K/AKT signaling pathways via the dephosphorylation 
of the C-terminal domain of PTEN, and the inhibition of the EMT process in OSCC 
[7]. Therefore, NDRG2 may regulate tumor EMT via different regulatory mecha-
nisms in different cancers.
7.  NDRG2 is involved in cancer metabolism by regulating glycolysis, 
glutaminolysis and fatty acid oxidation (FAO)
A cancerous cell undergoes multiple steps to form a solid tumor entity, dur-
ing which nutrient and oxygen supply insufficiencies frequently occur. In recent 
decades, studies have provided deep insight into cancer metabolism. In addition to 
glycolysis, metabolic alterations involve almost all metabolic pathways, including 
those of lipids, amino acids, nitrogen, and nucleic acids. Metabolic reprogramming 
is widely accepted to be a hallmark of cancer [52]. Cancer metabolic reprogram-
ming has been further summarized into six hallmarks, including alterations in 
nutrient uptake (deregulated uptake of glucose and amino acids and the use of 
opportunistic modes of nutrient acquisition) and intracellular metabolic pathways 
(the use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH pro-
duction and an increased demand for nitrogen) [53]. For instance, cancer cells use 
glucose and glutamine as the major sources of energy and precursor intermediates, 
thus exhibiting enhanced glycolysis and glutaminolysis [53]. Under various stress 
conditions, such as, glucose deficiency, cancer cells can shift from glycolysis to FAO 
to maintain ATP levels and satisfy nutrient demands [54]. Not surprisingly, onco-
gene activation and tumor suppressor inactivation are extensively involved in these 
processes. For example, c-Myc, HIF-1α, and p53 can regulate the uptake of both 
glucose and glutamine and glycolytic flux by affecting the expression of glucose 
transporters and metabolic enzymes [53].
As a tumor suppressor, NDRG2 was found to regulate aerobic glycolysis and 
glutaminolysis in cancer cells. A previous study from our laboratory showed that 
NDRG2 inhibits glucose uptake by interacting with and promoting the degrada-
tion of glucose transporter 1 (GLUT1) without affecting its transcription in breast 
cancer cell lines [55]. Recently, Xu et al. [56] from our laboratory, using colorectal 
cancer cells and a xenograft model, also demonstrated that NDRG2 inhibits glucose 
uptake and glycolysis by suppressing the expression and activity of the glucose 
transporter GLUT1 and key glycolytic enzymes, including hexokinase 2 (HK2), 
pyruvate kinase M2 isoform (PKM2) and lactate dehydrogenase A (LDHA). In 
addition, NDRG2 inhibits glutaminolysis by suppressing the expression of the 
glutamine transporter ASC amino acid transporter 2 (ASCT2) and glutaminase 1 
(GLS1) at the transcriptional level. Mechanistically, NDRG2 exerts such effects by 
suppressing the expression of β-catenin, leading to the repression of its target gene 
c-Myc. Since c-Myc is a master regulator of metabolism, additional in-depth studies 
on NDRG2’s regulatory role in other tumor glucose catabolism pathways are needed.
Under stress conditions such as glucose limitation, FAO is always activated to 
preserve the supply of ATP and NADPH [54]. Interestingly, our most recent study 
[4] revealed that NDRG2, as a negative regulator of AMPK, suppresses glucose 
deprivation-induced activation of the AMPK/ACC pathway and the consequent 
induction of FAO genes in hepatoma cells. Thus, NDRG2 overexpression leads to 
dysregulation of ATP and NADPH, thereby reducing the tolerance of hepatoma 
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cells to glucose limitation. Together, these data further our understanding of the 
tumor-suppressive mechanism of NDRG2 through its involvement in cancer meta-
bolic reprogramming. Therefore, the application of NDRG2 alone or in combination 
with antiglycolytic agents such as 2-diacylglycerol (2-DG) may effectively and 
synergistically inhibit cancer cells, which rely heavily on either glycolysis under 
non-stressful conditions or FAO under conditions of metabolic stress.
8. NDRG2 knockout enhances tumorigenesis in vivo
Most of the evidence for the role of NDRG2 as a tumor suppressor was mainly 
obtained in vitro, and establishing an in vivo mouse model to confirm these find-
ings was crucial. It is reported that Ndrg2-deficient mice are susceptible to sponta-
neous tumor formation in vivo and Ndrg2 knockout mice developed various types 
of tumors, including lymphomas, hepatocellular carcinomas and bronchoalveolar 
carcinomas [28]. However, we did not replicate these findings in our established 
Ndrg2 knockout mouse model—indeed, we did not detect any tumorigenesis in 
mice at 24 months of age. This discrepancy might be due to the different mouse 
strains and knockout strategies.
Notably, we established intestine-specific Ndrg2 knockout mice using a Villin-
Cre; Ndrg2flox/flox strategy [57]. Intestinal Ndrg2 deficiency significantly augmented 
colitis initiation and colitis-associated tumor development. Ndrg2 loss led to the 
destruction of adherens junction structure via E-cadherin reduction, resulting in 
diminished epithelial barrier function and enhanced gut permeability. We identi-
fied the novel mechanism by which NDRG2 is crucial for the interaction of the E3 
ligase FBXO11 with Snail, the repressor of E-cadherin. Thus, Ndrg2 loss increased 
Snail protein stability and decreased E-cadherin expression (https://www.biorxiv.
org/content/10.1101/473397v1). Moreover, our study revealed that NDRG2 is an 
essential intestinal epithelial barrier regulator and plays important roles in gut 
homeostasis maintenance and colitis-associated tumor development.
Recently, we established a liver cancer metastasis model in WT and Ndrg2 
knockout (Ndrg2−/−) mice and found that expression loss of the tumor suppressor 
Ndrg2 in the liver microenvironment significantly suppressed the growth of liver 
cell colonies [57, 58]. Our data highlighted the role of NDRG2 in the regulation of 
tumor-associated macrophage (TAM) polarization and its function in promoting 
cancer liver metastasis. Interestingly, a reduced metastatic burden was correlated 
with an increased percentage of M1-like TAMs and decreased expression of 
M2-associated markers in the NDRG2-deficient microenvironment [58]. In sum-
mary, our study is the first showing a crucial and unexpected role for NDRG2 in 
macrophage polarization and highlights the importance of investigating the func-
tion of NDRG2 in cancer cells and the tumor microenvironment differently.
9. NDRG2 in brain tumors and other nervous system diseases
Accumulating studies have shown that NDRG2 is associated with various 
nervous system diseases, including tumors, ischemic stroke, hemorrhage, trauma, 
and neurodegenerative disorders [1, 59]. NDRG2 was repeatedly reported to be 
downregulated in a variety of cerebral tumors, including glioma and meningioma 
[21, 60–66]. The transcription levels of human NDRG2 are significantly reduced 
in human glioblastoma tissues and human glioblastoma cell lines, and exogenous 
overexpression of NDRG2 repressed glioblastoma cell proliferation in vitro [2]. 
Although direct structural alterations such as point mutations are very rare in the 
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NDRG2 gene, hypermethylation of the NDRG2 promoter region was shown to be 
highly correlated with decreased NDRG2 transcription levels in human glioblas-
toma [60, 61, 67, 68]. In addition to the direct impact of NDRG2 hypermethylation 
per se, NDRG2 may control glioma cell growth by upregulating the levels of histone 
acetylation in glioma cells [62]. Moreover, the expression level of NDRG2 was 
negatively correlated with the pathological grade of the brain tumors and positively 
correlated with survival in astrocytoma patients [21, 63]. Consistent with the 
results in glioblastoma, a decrease in the levels of NDRG2 gene methylation and 
NDRG2 protein expression were detected in human meningioma [64]. In addition, 
the expression levels of NDRG2 were significantly further reduced in recurrent 
meningioma compared to that in primary meningioma [65]. The above results 
suggest that NDRG2 may be a potential biomarker for predicting the prognosis of 
human brain tumors.
NDRG family members are abundantly expressed in brain tissue; therefore, 
the significant functions of these NDRG2 family members in the central nervous 
system were anticipated and have been confirmed with NDRG gene knockout mice-
based studies [69–71]. NDRG1 deficiency leads to a progressive demyelinating in 
the peripheral nerves, suggesting that NDRG1 is involved in the maintenance of and 
axonal survival and myelin sheath structure [69]. Ndrg2−/− mice exhibited typical 
ADHD-like behaviors, including hyperactivity, impulsivity, and inattention, as well 
as impaired memory [70]. Ndrg4−/− mice showed impaired cognition and increased 
susceptibility to ischemic stroke, indicating that NDRG4 has a potential neuropro-
tective effect [71].
In addition, NDRG2 was implicated in the ischemic stress response in several 
in vivo and in vitro studies [72–78]. Temporal and spatial patterns of NDRG2 
expression in the rat brain were investigated after transient middle cerebral artery 
occlusion and reperfusion. Both the mRNA and protein levels of NDRG2 were 
increased following reperfusion in the ischemic penumbra, and NDRG2 was trans-
located from the cytoplasm to the nucleus in astrocytes. Moreover, NDRG2 expres-
sion increased in parallel with the enhancement of TUNEL signals in this ischemic 
animal model [73]. It is consistent with the results of the animal experiments 
described above, the expression of NDRG2 was also revealed to be upregulated 
and NDRG2 can translocate from the cytoplasm to the nucleus in C6-originated 
astrocytes after oxygen-glucose deprivation (OGD) treatment mimicking ischemic 
model in vitro [72]. Furthermore, NDRG2 was implicated in some types of cerebral 
ischemic preconditioning-mediated neuroprotection, including electroacupuncture 
(EA) [75] and sevoflurane preconditioning [74]. EA preconditioning in the Baihui 
acupoint was performed before transient focal cerebral ischemia and reperfusion. 
After EA pretreatment, the number of apoptotic cells in the ischemic penumbra and 
the volume of cerebral infarct were significantly decreased, and the neurological 
outcomes were effectively rescued. After ischemia treatment, the levels of NDRG2 
expression were largely suppressed in the EA pretreatment group compared with 
sham group. And NDRG2 was mostly localized in the astroglial cytoplasm; only 
weak staining was found in the astroglial nucleus after EA pretreatment. However, 
NDRG2 protein was remarkably transferred from the cytoplasm into the nucleus in 
the sham group [75]. Recently, NDRG2 was also found to exhibit neuroprotective 
effects with sevoflurane preconditioning in brain ischemia models both in vivo 
and in vitro [74]. These results together indicate that NDRG2 takes part in the 
pathological process of brain ischemia-reperfusion injury and that NDRG2 may be a 
potential intervention target for ischemic stroke.
NDRG2 has also been repeatedly reported to be associated with other nervous 
system diseases, such as, neurodegeneration [79–81] and depression [82–84]. 
NDRG2 has been identified as one of six aberrantly phosphorylated proteins in 
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human brains with frontotemporal lobe degeneration, and an increased phospho-
spectra of NDRG2 was found in these neurodegenerative tissues [85]. Accumulated 
NDRG2 and GFAP were detected in cortical senile plaques from the postmortem 
human brain tissues with Alzheimer’s disease (AD) [79]. In addition, the expres-
sion levels of NDRG2 and GFAP were parallelly increased in amyloid precursor 
protein (APP)/presenilin (PS1) mouse, a double transgenic AD mouse model 
[80]. Suppressed NDRG2 expression and decreased memory impairment were 
detected in parallel after EA treatment to APP/PS1 transgenic mice. Furthermore, 
the increased reactive astrocytes andNDRG2 expression were detected in the mice 
which were exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a Parkinson’s 
disease-associated neurotoxin that causes both glial activation and neurodegenera-
tion [86]. Moreover, growing studies have demonstrated that NDRG2 is related 
with the function of antidepressants, which can correct depression-like behaviors 
and alleviate neural damages observed in depressive animals [82–84]. NDRG2 was 
downregulated in the rat frontal cortex after chronic use of antidepressants [84]. 
In contrast to the results described above antidepressants did not counteract the 
increase in NDRG2 expression in the hippocampus of rats with stress-induced 
depression-like symptoms and that antidepressants per se induced NDRG2 expres-
sion in normal rats [83]. Further study of the detailed mechanisms by which 
NDRG2 participates in these neurodegenerative or chronic psychiatric diseases 
providing novel intervention strategies will thus be interesting.
10. Conclusion and perspectives
To date, both in vitro and in vivo evidence has shown that NDRG2 can inhibit 
cancer cell proliferation, EMT, metastasis and can promote cell differentiation and 
cell cycle arrest. Thus, NDRG2 might be a target for cancer treatment and therapeu-
tic resistance. Although NDRG2 is a novel tumor suppressor, the detailed mecha-
nism by which NDRG2 functions requires further elucidation. Moreover, additional 
in vivo data are needed to confirm its tumor suppressor function.
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